| 须新涛 耿辉 黄建峰 黄浒平 秦锡虎.肝动脉化疗栓塞联合索拉菲尼治疗中晚期肝细胞癌的临床疗效评估[J].,2016,16(15):2935-2937 |
| 肝动脉化疗栓塞联合索拉菲尼治疗中晚期肝细胞癌的临床疗效评估 |
| Advanced Hepatocellular Carcinoma: Clinical Efficacy of TranscatheterArterial Chemoembolization Combined with Sorafenib |
| |
| DOI： |
| 中文关键词: 肝动脉化疗栓塞 索拉菲尼 中晚期肝细胞癌 临床疗效 |
| 英文关键词: Transcatheter arterial chemoembolization Sorafenib Advanced hepatocellular carcinoma Clinical efficacy |
| 基金项目:江苏省自然科学基金项目（BK2012588） |
|
| 摘要点击次数: 870 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨中晚期肝细胞癌（HCC）采用肝动脉化疗栓塞联合索拉菲尼治疗的临床疗效。方法：按照随机数字表法将2012 年
3 月-2014 年3 月我院收治的中晚期HCC患者分为两组，对照组行肝动脉化疗栓塞术治疗，观察组在对照组基础上联合索拉菲
尼治疗。比较两组的疗效，毒副反应及远期生存率。结果：观察组患者治疗后6 个月的临床疗效优于对照组，差异有统计学意义
（Z=-2.316，P=0.021），观察组有效率52.50%，高于对照组的28.21%，差异有统计学意义（x2=4.837，P=0.028）。治疗后观察组手足皮
肤反应和口腔黏膜炎症的发生率为22.50%、25.00%，分别高于对照组的5.13%、5.13%，差异有统计学意义（P<0.05）。观察组6、12
个月的生存率为95.00%、85.00%，分别高于对照组的79.49%、64.10%，差异有统计学意义（P<0.05）。结论：肝动脉化疗栓塞联合索
拉菲尼治疗HCC 具有疗效好、明显延长患者生存时间的特点，临床有重要的参考价值。 |
| 英文摘要: |
| Objective:To explore the clinical efficacy of transcatheter arterial chemoembolization combined with sorafenib in the
treatment of patients with advanced hepatocellular carcinoma (HCC).Methods:The patients with advanced HCC, who were admitted to
Changzhou Traditional Chinese Medicine Hospital from March 2012 to March 2014, were randomly divided into control group and observation
group. The control group was treated by transcatheter arterial chemoembolization, while the observation group was added sorafenib
based on the therapy of control group. Then the clinical efficacy,incidence of adverse reactions and survival rate in the two groups
wee compared.Results:The clinical efficacy of observation group after 6 months of treatment was better than that of control group, the
difference was statistically significant(Z=-2.316, P=0.021); the effective rate(52.50%) of observation group was higher than that(28.21%)
of control group, the difference was statistically significant(x2=4.837, P=0.028). The incidence of hand foot skin reaction and mucosal inflammation
in the observation group were 22.50%and 25.00%, which were higher than those(5.13%) and (5.13) respectively in the control
group, the differences were statistically significant(P<0.05). The survival rate(95.%%and 85.00%) of observation group for 6 months
and 12 months were higher than those (79.49% and 64.10%) of control group, the differences were statistically significant(P<0.05).Conclusion:Transcatheter arterial chemoembolization combined with sorafenib in the treatment of patients with advanced HCC has the
characteristics of good clinical efficacy and prolonging the survival time, which has an important reference value in the clinical field. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
